Comparative Pharmacology
Head-to-head clinical analysis: DILAUDID versus NORCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILAUDID versus NORCET.
DILAUDID vs NORCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
Combination analgesic: hydrocodone acts as a μ-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system, exerting central analgesic and antipyretic effects.
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
1-2 tablets (containing paracetamol 325 mg and tramadol 37.5 mg) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
None Documented
None Documented
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
2-4 hours (terminal); prolonged in hepatic impairment (up to 8-10 hours) and elderly
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Renal: ~60% unchanged; hepatic metabolism to inactive glucuronide conjugates; biliary/fecal: <5%
Category C
Category C
Opioid Analgesic
Opioid Analgesic